

Cover Story
NCINews Analysis
Love them or hate them, site visits have been a part of the culture of NCI-designated cancer centers for decades, shaping the process for admitting members to the elite club and influencing internal politics within institutions.
Cancer Policy
In Brief


Clinical Roundup


Drugs & Targets



CURRENT ISSUE



CURRENT ISSUE
Trending Stories
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
- Cancer centers adapt to life without site visits as NIH changes CCSG review
- How GLP-1RA drugs are reshaping patient physiology and the future of oncology
- Jonathan Licht named president, chief scientific officer at Van Andel Institute
- Friends publishes three white papers ahead of annual meeting
Topics: Clinical trials on rare cancers, combination drug trials, multi-regional studies - Early endpoints are a balance of risk and benefit












